HST Global, Inc. (HSTC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HST Global, Inc. (HSTC) with AI Score 52/100 (Hold). HST Global, Inc. is a biotechnology company focused on developing and acquiring wellness centers for homeopathic and alternative cancer treatments. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026HST Global, Inc. (HSTC) Healthcare & Pipeline Overview
HST Global, Inc. operates as an integrated health and wellness biotechnology company, focusing on homeopathic and alternative treatments for late-stage cancer. With a network of wellness centers and a pipeline of homeopathic product candidates, HSTC navigates a competitive landscape in the biotechnology sector, marked by high-risk, high-reward ventures.
Investment Thesis
Investing in HST Global, Inc. presents a high-risk, high-reward scenario. The company's focus on homeopathic and alternative cancer treatments offers potential for significant growth in a niche market. However, HSTC's negative P/E ratio of -112.73 and a profit margin of -153.5% indicate substantial financial challenges. The company's beta of -1.24 suggests a negative correlation with the market, which could provide some downside protection during market downturns. Growth catalysts include the successful development and commercialization of its homeopathic product candidates, as well as the expansion of its network of wellness centers. The company's ability to secure regulatory approvals and demonstrate the efficacy of its treatments will be crucial for its long-term success. Investors should carefully consider the risks associated with investing in a small-cap biotechnology company operating in the highly competitive and regulated healthcare sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -112.73 reflects current unprofitability and significant losses.
- Profit margin of -153.5% highlights the company's challenges in achieving profitability.
- Gross margin of 61.2% suggests strong pricing power on existing products, but needs to be scaled.
- Beta of -1.24 indicates a negative correlation with the market, potentially offering downside protection.
Competitors & Peers
Strengths
- Focus on a niche market (homeopathic cancer treatments).
- Integrated approach with wellness centers and product candidates.
- Potential for high growth in the alternative medicine market.
- Proprietary treatment formulas and expertise.
Weaknesses
- Limited financial resources and profitability.
- High dependence on regulatory approvals.
- Small market capitalization and liquidity.
- Limited brand recognition and market presence.
Catalysts
- Upcoming: Results from ongoing clinical trials for homeopathic product candidates.
- Ongoing: Expansion of the network of wellness centers through acquisitions and development.
- Ongoing: Strategic partnerships and collaborations with healthcare companies and research institutions.
Risks
- Potential: Failure to obtain regulatory approvals for its product candidates.
- Ongoing: Intense competition from established pharmaceutical companies.
- Potential: Negative perception of homeopathic treatments and lack of scientific validation.
- Ongoing: Limited financial resources and profitability challenges.
- Potential: Risk of clinical trial failures and setbacks.
Growth Opportunities
- Expansion of Wellness Center Network: HST Global has the opportunity to expand its network of wellness centers globally. The global wellness market is estimated to be worth trillions of dollars, with a growing demand for alternative and holistic healthcare solutions. By acquiring and developing new wellness centers, HSTC can increase its revenue streams and establish a stronger presence in key markets. Timeline: Ongoing.
- Development and Commercialization of Homeopathic Product Candidates: HST Global's pipeline of homeopathic product candidates represents a significant growth opportunity. Successful clinical trials and regulatory approvals could lead to the commercialization of new treatments for late-stage cancers and other life-threatening diseases. The market for cancer therapeutics is substantial, with a growing demand for targeted and personalized therapies. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: HST Global can pursue strategic partnerships and collaborations with other healthcare companies, research institutions, and wellness organizations. These partnerships can provide access to new technologies, expertise, and markets. Collaborations can also help to accelerate the development and commercialization of HSTC's product candidates. Timeline: Ongoing.
- Geographic Expansion: HST Global can expand its operations into new geographic markets, particularly in regions with a high prevalence of cancer and a growing demand for alternative treatments. Emerging markets in Asia and Latin America offer significant growth potential. Expanding into new markets will require careful planning and execution, including regulatory compliance and market entry strategies. Timeline: 2-4 years.
- Increased Investment in Research and Development: HST Global can increase its investment in research and development to accelerate the discovery and development of new homeopathic treatments. Investing in R&D will require careful allocation of resources and a focus on promising areas of research. Successful R&D efforts could lead to the development of breakthrough therapies and a stronger competitive position. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets.
- Strategic partnerships and collaborations.
- Increased investment in research and development.
- Growing demand for alternative cancer treatments.
Threats
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements and potential delays.
- Negative perception of homeopathic treatments.
- Risk of clinical trial failures.
Competitive Advantages
- Proprietary homeopathic treatment formulas.
- Established network of wellness centers.
- Expertise in homeopathic and alternative cancer therapies.
- Potential for intellectual property protection through patents and trademarks.
About HSTC
HST Global, Inc. is a biotechnology company focused on the development and acquisition of wellness centers specializing in homeopathic and alternative treatments for late-stage cancer patients. The company's mission is to provide integrated health and wellness solutions through a combination of wellness centers and homeopathic product candidates. These candidates are either undergoing or have completed clinical testing for the treatment of late-stage cancers and other life-threatening diseases. Headquartered in Hampton, Virginia, HST Global operates within the broader healthcare sector, specifically targeting the biotechnology and alternative medicine markets. The company aims to establish a global network of wellness centers, offering patients access to a range of homeopathic and alternative therapies. HST Global's strategy involves not only developing its own product candidates but also acquiring existing wellness centers to expand its reach and service offerings. The company's focus on homeopathic and alternative treatments sets it apart from traditional pharmaceutical companies, positioning it within a niche market that caters to patients seeking alternative approaches to cancer treatment. HST Global's success hinges on its ability to navigate the regulatory landscape, demonstrate the efficacy of its treatments, and build a strong network of wellness centers worldwide.
What They Do
- Develops and acquires wellness centers for homeopathic and alternative cancer treatment.
- Focuses on homeopathic and alternative product candidates for late-stage cancers.
- Conducts clinical testing for its product candidates.
- Aims to provide integrated health and wellness solutions.
- Operates in the biotechnology and alternative medicine markets.
- Seeks to establish a global network of wellness centers.
Business Model
- Generates revenue through the operation of wellness centers.
- Derives income from the sale of homeopathic and alternative treatment products.
- May receive funding through partnerships and collaborations.
- Potentially generates revenue through licensing agreements for its product candidates.
Industry Context
HST Global, Inc. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in genomics, personalized medicine, and biopharmaceuticals. HSTC's focus on homeopathic and alternative cancer treatments places it in a niche segment of this market. Competitors include companies like ARDS, BTAX, EVLO, GSRX, and INFIQ, which are also involved in various aspects of biotechnology and healthcare. HST Global's success will depend on its ability to differentiate itself through innovative treatments and effective marketing strategies.
Key Customers
- Late-stage cancer patients seeking alternative treatment options.
- Individuals interested in homeopathic and holistic healthcare solutions.
- Wellness centers and healthcare providers looking to offer alternative therapies.
- Potential partners and collaborators in the healthcare industry.
Financials
Chart & Info
HST Global, Inc. (HSTC) stock price: Price data unavailable
Latest News
No recent news available for HSTC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSTC.
Price Targets
Wall Street price target analysis for HSTC.
MoonshotScore
What does this score mean?
The MoonshotScore rates HSTC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Michael Fortkort
CEO
Michael Fortkort serves as the Chief Executive Officer of HST Global, Inc. His background includes experience in the healthcare and biotechnology sectors. He has been involved in the development and management of companies focused on alternative and homeopathic treatments. Fortkort's leadership is focused on driving the company's growth through strategic acquisitions and the development of innovative product candidates. His expertise lies in navigating the complex regulatory landscape and building partnerships to expand the company's reach.
Track Record: Under Michael Fortkort's leadership, HST Global, Inc. has focused on expanding its network of wellness centers and advancing its pipeline of homeopathic product candidates. Key milestones include the acquisition of new wellness centers and the initiation of clinical trials for its lead product candidates. Fortkort has also been instrumental in securing funding and establishing strategic partnerships to support the company's growth initiatives.
HSTC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that may not meet the minimum financial standards or have chosen not to provide current information to the market. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies often have limited regulatory oversight and reporting requirements. This tier includes a wide range of companies, some of which may be defunct, distressed, or have questionable business practices. Investing in OTC Other companies carries a significantly higher level of risk compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Lack of analyst coverage and institutional interest.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has an operating history.
- Company has a functioning website and contact information.
- CEO is identified.
- Company is focused on a specific market (homeopathic cancer treatments).
HSTC Healthcare Stock FAQ
What does HST Global, Inc. do?
HST Global, Inc. is an integrated health and wellness biotechnology company that focuses on developing and acquiring wellness centers specializing in homeopathic and alternative treatments for late-stage cancer. The company also develops homeopathic product candidates that are undergoing or have completed clinical testing for the treatment of late-stage cancers and other life-threatening diseases. HST Global aims to provide a holistic approach to cancer treatment by combining wellness centers with homeopathic therapies.
What do analysts say about HSTC stock?
As of 2026-03-17, there is no readily available analyst coverage for HSTC stock due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio (-112.73) and profit margin (-153.5%) indicate that the company is currently unprofitable. Investors should carefully consider the risks and potential rewards associated with investing in a small-cap biotechnology company operating in the alternative medicine market. Further research and due diligence are recommended before making any investment decisions.
What are the main risks for HSTC?
The main risks for HSTC include the potential failure to obtain regulatory approvals for its homeopathic product candidates, intense competition from established pharmaceutical companies, and the negative perception of homeopathic treatments. Additionally, the company faces financial risks due to its limited resources and profitability challenges. Clinical trial failures and setbacks could also negatively impact the company's prospects. The OTC listing adds additional risks related to liquidity and transparency.
What are the key factors to evaluate for HSTC?
HST Global, Inc. (HSTC) currently holds an AI score of 52/100, indicating moderate score. Key strength: Focus on a niche market (homeopathic cancer treatments).. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for its product candidates.. This is not financial advice.
How frequently does HSTC data refresh on this page?
HSTC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HSTC's recent stock price performance?
Recent price movement in HST Global, Inc. (HSTC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on a niche market (homeopathic cancer treatments).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HSTC overvalued or undervalued right now?
Determining whether HST Global, Inc. (HSTC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HSTC?
Before investing in HST Global, Inc. (HSTC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis pending for HSTC may provide further insights.